Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heleen J Bouman

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Thrombosis Research|May 11, 2010
The Cone-and-Plate(let) analyzer is not suitable to monitor clopidogrel therapy: a comparison with the flowcytometric VASP assay and optical aggregometryJochem W van Werkum, Heleen J Bouman, Nicoline J Breet, et al.
Expert Opinion on Medical Diagnostics|March 16, 2013
Platelet function tests for the monitoring of P2Y12 inhibitorsNicoline J Breet, Jochem W van Werkum, Heleen J Bouman, et al.
BMJ (Clinical Research Ed.)|August 6, 2011
Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysisTim Bauer, Heleen J Bouman, Jochem W van Werkum, et al.
Thrombosis and Haemostasis|June 30, 2011
The relationship between platelet reactivity and infarct-related artery patency in patients presenting with a ST-elevation myocardial infarctionNicoline J Breet, Jochem W van Werkum, Heleen J Bouman, et al.
International Journal of Cardiology|December 19, 2008
A comparison between the Plateletworks-assay and light transmittance aggregometry for monitoring the inhibitory effects of clopidogrelJochem W van Werkum, Marjolein Kleibeuker, Sonja Postma, et al.
Heart (British Cardiac Society)|April 12, 2011
High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary interventionNicoline J Breet, Jochem W van Werkum, Heleen J Bouman, et al.
Clinical Kidney Journal|October 10, 2024
The effects of dialysate calcium prescription on mortality outcomes in incident patients on hemodialysisKarlien J Ter Meulen, Paola Carioni, Francesco Bellocchio, et al.
Nature Medicine|December 21, 2010
Paraoxonase-1 is a major determinant of clopidogrel efficacyHeleen J Bouman, Edgar Schömig, Jochem W van Werkum, et al.
Heart (British Cardiac Society)|June 2, 2011
Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stentingHeleen J Bouman, Ankie M Harmsze, Jochem W van Werkum, et al.
Circulation. Cardiovascular Genetics|December 25, 2009
Common variation in the platelet receptor P2RY12 gene is associated with residual on-clopidogrel platelet reactivity in patients undergoing elective percutaneous coronary interventionsGoran Rudez, Heleen J Bouman, Jochem W van Werkum, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Thrombosis Research|May 11, 2010
The Cone-and-Plate(let) analyzer is not suitable to monitor clopidogrel therapy: a comparison with the flowcytometric VASP assay and optical aggregometryJochem W van Werkum, Heleen J Bouman, Nicoline J Breet, et al.
Expert Opinion on Medical Diagnostics|March 16, 2013
Platelet function tests for the monitoring of P2Y12 inhibitorsNicoline J Breet, Jochem W van Werkum, Heleen J Bouman, et al.
BMJ (Clinical Research Ed.)|August 6, 2011
Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysisTim Bauer, Heleen J Bouman, Jochem W van Werkum, et al.
Thrombosis and Haemostasis|June 30, 2011
The relationship between platelet reactivity and infarct-related artery patency in patients presenting with a ST-elevation myocardial infarctionNicoline J Breet, Jochem W van Werkum, Heleen J Bouman, et al.
International Journal of Cardiology|December 19, 2008
A comparison between the Plateletworks-assay and light transmittance aggregometry for monitoring the inhibitory effects of clopidogrelJochem W van Werkum, Marjolein Kleibeuker, Sonja Postma, et al.
Heart (British Cardiac Society)|April 12, 2011
High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary interventionNicoline J Breet, Jochem W van Werkum, Heleen J Bouman, et al.
Clinical Kidney Journal|October 10, 2024
The effects of dialysate calcium prescription on mortality outcomes in incident patients on hemodialysisKarlien J Ter Meulen, Paola Carioni, Francesco Bellocchio, et al.
Nature Medicine|December 21, 2010
Paraoxonase-1 is a major determinant of clopidogrel efficacyHeleen J Bouman, Edgar Schömig, Jochem W van Werkum, et al.
Heart (British Cardiac Society)|June 2, 2011
Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stentingHeleen J Bouman, Ankie M Harmsze, Jochem W van Werkum, et al.
Circulation. Cardiovascular Genetics|December 25, 2009
Common variation in the platelet receptor P2RY12 gene is associated with residual on-clopidogrel platelet reactivity in patients undergoing elective percutaneous coronary interventionsGoran Rudez, Heleen J Bouman, Jochem W van Werkum, et al.
Pageof 2